PolyTherics Ltd - News on 16 June 2008

2008
PolyTherics and Alligator Bioscience announces strategic collaboration for optimisation of next generation biopharmaceuticals
Secretary of State John Denham visits PolyTherics
Novel Approach to Drug Insolubility strengthens PolyTherics patent estate
PolyTherics expands Collaboration with Biocompatibles
PolyTherics-Celtic Pharma Collaboration Agreement to explore technologies for improved drug performance
New Consortium announces Significant Grant Funding of Anaemia product programme

2007
Innovative Drug Production Project secures funding from Technology Strategy Board
Imperial Innovations Annual Report - PolyTherics Limited
PolyTherics highlighted by UK Trade & Investment
Antony Godwin from PolyTherics ties the knot
PolyTherics and BioVectra dcl sign Manufacturing and Representation Deal
Innovative Biopharmaceutical Company, PolyTherics, raises over £2 million
TheraPEG ™ technology ideal for drugs for developing countries

2006
TheraPEG ™ technology wins Research Breakthrough Award
NHS at Hammersmith Hospital applauds new PEGylated IFN
PolyTherics nominated Regional Finalist in UK Biotechnology Entrepreneur Awards 2006
PolyTherics PEGylation technology published in Nature
Debbie Allen and Geeta Gupta joins PolyTherics

2005
PolyTherics and Shantha sign biotech deal
BangaloreBio begins
British High Commissioner addresses Indian biotech companies

Previous
PolyTherics Ltd and Alligator Bioscience AB announce strategic collaboration for optimisation of next generation biopharmaceuticals

PolyTherics Ltd ("PolyTherics"), a biopharmaceutical company specialised in the targeted application of polymers to biopharmaceuticals, and Alligator Bioscience AB ("Alligator"), a biotechnology company applying proprietary technology to the improvement of proteins, today announced the establishment of a new alliance.

Under the terms of the collaboration agreement, PolyTherics and Alligator will explore the biological effects of the polymer-based technologies developed by PolyTherics on proteins optimized and provided by Alligator. The parties intend to use the intellectual property generated by their collaboration to explore the development and commercialization potential of next generation protein-based products. No further details were disclosed.

Dr Keith Powell, Chief Executive Officer of PolyTherics, said: "A key element of PolyTherics' business strategy is to exploit our proprietary technologies in expanding the product potential of proteins. We have developed and continue to develop technologies to improve every type of protein therapeutic; from antibody fragments to enzymes, both natural and improved. We are excited by the prospects for this collaboration with Alligator and our shared vision of exploring next generation biopharmaceuticals."

Dr Gun-Britt Fransson, Chief Executive Officer of Alligator, commented: "The collaboration with PolyTherics supports Alligator's strategy to further expand its pipeline with optimised drug candidates into new areas of indications. We are excited to see the outcome of combining the two companies technologies."

---
16 June 2008

Previous